Security
Lucid Diagnostics Inc. Common Stock · LUCD
LUCDNASDAQCommon stockCurrentCIK 1799011Updated Oct 23, 2026
LUCD price & chart
Loading TradingView…
NASDAQ:LUCD on TradingView ↗About the company
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
In the news
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways ↗
Seeking Alpha
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens ↗
Lucid Diagnostics Inc. 2026 Q2 - Results - Earnings Call Presentation ↗
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript ↗
SEC disclosures
Lucid Diagnostics Inc. files 8-K: Material Event ↗
Recent filings
Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.02, 3.03, 5.03, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 53,198,000Source | 22,598,000Source | 38,946,000Source | 38,670,000Source | 34,113,000Source | 34,080,000Source | 32,795,000Source | 32,048,000Source | 40,445,000Source | 30,715,000Source | 27,270,000Source | 32,509,000Source |
| Property, Plant and Equipment, NetUSD | 862,000Source | 940,000Source | 810,000Source | 948,000Source | 1,050,000Source | 907,000Source | 1,040,000Source | 1,242,000Source | 809,000Source | 1,062,000Source | 1,334,000Source | 1,592,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 421,000Source | 842,000Source | 105,000Source | 526,000Source | 947,000Source | 210,000Source | 631,000Source | 1,052,000Source | 315,000Source | 736,000Source | 1,424,000Source | 3,445,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 47,332,000Source | 14,489,000Source | — | 31,123,000Source | 24,920,000Source | — | 25,238,000Source | 24,769,000Source | — | 22,358,000Source | 18,896,000Source | 22,474,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 550,000Source | 39,000Source | 1,088,000Source | 373,000Source | 160,000Source | 689,000Source | 61,000Source | 49,000Source | 643,000Source | 45,000Source | 45,000Source | 17,000Source |
| Inventory, NetUSD | 486,000Source | 651,000Source | 484,000Source | 505,000Source | 683,000Source | 469,000Source | 484,000Source | 410,000Source | 353,000Source | 341,000Source | 278,000Source | — |
| Assets, CurrentUSD | 49,842,000Source | 16,824,000Source | 36,623,000Source | 33,833,000Source | 27,947,000Source | 31,362,000Source | 27,537,000Source | 27,583,000Source | 37,468,000Source | 25,148,000Source | 22,073,000Source | 24,356,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,474,000Source | 1,645,000Source | 1,647,000Source | 1,832,000Source | 2,184,000Source | 2,328,000Source | 1,754,000Source | 2,355,000Source | 1,767,000Source | 2,404,000Source | 2,854,000Source | 1,865,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,021,000Source | 2,860,000Source | 1,398,000Source | 2,238,000Source | 3,037,000Source | 1,591,000Source | 2,454,000Source | 1,039,000Source | 1,806,000Source | 2,637,000Source | 1,307,000Source | 2,008,000Source |
| Other Assets, NoncurrentUSD | 52,000Source | 1,132,000Source | 10,000Source | 1,125,000Source | 1,132,000Source | 10,000Source | 1,133,000Source | 1,132,000Source | 47,000Source | 1,132,000Source | 1,132,000Source | 1,108,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 27,363,000Source | 16,260,000Source | 28,019,000Source | 30,808,000Source | 18,134,000Source | 30,080,000Source | 38,172,000Source | 20,154,000Source | 29,509,000Source | 25,324,000Source | 29,581,000Source | 9,462,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 54,274,000Source | 55,919,000Source | 0Source | 54,419,000Source | 55,919,000Source | 10,134,000Source | 54,419,000Source | 44,285,000Source | 54,274,000Source | 54,419,000Source | 18,625,000Source | — |
| Common Stock, Value, IssuedUSD | 131,000Source | 52,000Source | 191,000Source | 102,000Source | 49,000Source | 165,000Source | 84,000Source | 47,000Source | 131,000Source | 63,000Source | 42,000Source | 41,000Source |
| Additional Paid in CapitalUSD | 229,499,000Source | 142,592,000Source | 323,414,000Source | 201,013,000Source | 139,865,000Source | 291,664,000Source | 179,904,000Source | 136,411,000Source | 230,866,000Source | 154,675,000Source | 129,763,000Source | 121,081,000Source |
| Retained Earnings (Accumulated Deficit)USD | -258,069,000Source | -192,225,000Source | -312,678,000Source | -247,672,000Source | -179,854,000Source | -297,963,000Source | -239,784,000Source | -168,849,000Source | -274,335,000Source | -203,766,000Source | -150,741,000Source | -98,075,000Source |
| Stockholders' Equity Attributable to ParentUSD | 25,835,000Source | 6,338,000Source | 10,927,000Source | 7,862,000Source | 15,979,000Source | 4,000,000Source | -5,377,000Source | 11,894,000Source | 10,936,000Source | 5,391,000Source | -2,311,000Source | 23,047,000Source |
| Liabilities and EquityUSD | 53,198,000Source | 22,598,000Source | 38,946,000Source | 38,670,000Source | 34,113,000Source | 34,080,000Source | 32,795,000Source | 32,048,000Source | 40,445,000Source | 30,715,000Source | 27,270,000Source | 32,509,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 26,206,000Source | 14,249,000Source | 27,516,000Source | 29,426,000Source | 15,980,000Source | 29,385,000Source | 36,569,000Source | 19,977,000Source | 28,582,000Source | 23,524,000Source | 29,382,000Source | 8,425,000Source |
| Operating Lease, Liability, CurrentUSD | 878,000Source | 855,000Source | 906,000Source | 871,000Source | 884,000Source | 908,000Source | 867,000Source | 861,000Source | 893,000Source | 854,000Source | 1,106,000Source | 962,000Source |
| Accounts Payable, CurrentUSD | 751,000Source | 1,135,000Source | 667,000Source | 833,000Source | 903,000Source | 1,077,000Source | 829,000Source | 969,000Source | 970,000Source | 1,241,000Source | 1,146,000Source | 1,056,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,157,000Source | 2,011,000Source | 503,000Source | 1,382,000Source | 2,154,000Source | 695,000Source | 1,603,000Source | 177,000Source | 927,000Source | 1,800,000Source | 199,000Source | 1,037,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | 2,443,000Source | — | — | 2,200,000Source | — | — | 2,719,000Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 222,000Source | 221,000Source | 872,000Source | 1,167,000Source | 2,499,000Source | 1,936,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 949,000Source | — | 4,183,000Source | 5,762,000Source | 13,859,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 46,000Source | 16,000Source | 601,000Source | — | 28,000Source | -183,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 108,000Source | -412,000Source | -270,000Source | 96,000Source | 89,000Source | -445,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,101,000Source | -12,465,000Source | -46,485,000Source | -44,140,000Source | -32,817,000Source | -29,685,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -215,000Source | -93,000Source | -197,000Source | -646,000Source | -221,000Source | -4,108,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 215,000Source | 93,000Source | 197,000Source | — | — | 3,200,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 5,487,000Source | 15,438,000Source | 59,029,000Source | 48,248,000Source | 29,460,000Source | 2,611,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -6,829,000Source | 2,880,000Source | 12,347,000Source | 3,462,000Source | -3,578,000Source | -31,182,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,152,000Source | 1,228,000Source | 1,694,000Source | 1,143,000Source | 1,411,000Source | 1,030,000Source | 4,491,000Source | 4,534,000Source | 6,822,000Source | 14,991,000Source |
| Amortization of Intangible AssetsUSD | — | — | 105,000Source | 105,000Source | 105,000Source | 105,000Source | 105,000Source | 105,000Source | 421,000Source | 688,000Source | 2,021,000Source | 1,649,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 451,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | -435,000Source | — | — | — | — | 0Source | -5,167,000Source | -26,000Source | — |
| General and Administrative ExpenseUSD | — | — | 5,605,000Source | 5,355,000Source | 5,757,000Source | 5,617,000Source | 5,432,000Source | 6,162,000Source | 23,867,000Source | 20,156,000Source | 19,254,000Source | 23,685,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | — | — | 4,000Source | 6,000Source | 6,000Source | 9,000Source | 22,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | 77,000Source | 110,000Source | 70,000Source | 66,000Source | 386,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,397,000Source | -12,371,000Source | -11,687,000Source | -4,439,000Source | -13,909,000Source | -26,908,000Source | -58,010,000Source | -45,529,000Source | -52,666,000Source | -56,171,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -10,397,000Source | -12,371,000Source | -14,715,000Source | -7,888,000Source | -23,628,000Source | -36,018,000Source | -70,569,000Source | -53,025,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | — | — | 1,114,000Source | 6,945,000Source | -1,795,000Source | -14,421,000Source | -8,370,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 12,970,000Source | 12,866,000Source | — | 12,547,000Source | — | 13,315,000Source | — | 50,398,000Source | 50,910,000Source | 56,548,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | 2,600,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 1,362,000Source | -677,000Source | — | 6,945,000Source | — | -14,421,000Source | — | 523,000Source | -4,184,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 1,807,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 20,000Source | 3,000Source | 17,000Source | 4,000Source | — | 695,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | 1,474,000Source | 1,163,000Source | 1,256,000Source | 828,000Source | 4,706,000Source | — | — | — |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,211,000Source | 1,172,000Source | — | 1,163,000Source | — | 828,000Source | — | 4,346,000Source | 2,428,000Source | 377,000Source |
| Cost of RevenueUSD | — | — | — | — | 1,445,000Source | 1,563,000Source | 1,625,000Source | 1,551,000Source | 6,670,000Source | — | — | 100,000,000Source |
| Operating Income (Loss)USD | — | — | -11,759,000Source | -11,694,000Source | -12,801,000Source | -11,384,000Source | -12,114,000Source | -12,487,000Source | -49,640,000Source | -46,052,000Source | -48,482,000Source | -56,171,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,362,000Source | -677,000Source | — | 6,945,000Source | — | -14,421,000Source | — | 523,000Source | -4,184,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -10,397,000Source | -12,371,000Source | -11,687,000Source | -4,439,000Source | -13,909,000Source | -26,908,000Source | -58,010,000Source | -45,529,000Source | -52,666,000Source | -56,171,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,397,000Source | -12,371,000Source | -11,687,000Source | -4,439,000Source | -13,909,000Source | -26,908,000Source | -58,010,000Source | -45,529,000Source | -52,666,000Source | -56,171,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.1Source | -0.25Source | -0.08Source | -0.08Source | -0.17Source | -0.52Source | -0.69Source | -1.05Source | -1.26Source | -1.55Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.1Source | -0.25Source | — | -0.08Source | — | -0.52Source | — | -1.05Source | -1.26Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 108,176,088Source | 50,374,146Source | 183,124,412Source | 98,989,161Source | 140,096,782Source | 68,796,392Source | 101,946,871Source | 50,515,773Source | 41,756,129Source | 36,172,421Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 108,176,088Source | 50,374,146Source | — | 98,989,161Source | — | 68,796,392Source | — | 50,515,773Source | 41,756,129Source | — |
| Interest Expense (non-operating)USD | — | — | — | — | 4,000Source | 6,000Source | 6,000Source | 9,000Source | 22,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 105,000Source | 105,000Source | 105,000Source | 105,000Source | 105,000Source | 105,000Source | 421,000Source | 688,000Source | 2,021,000Source | 1,649,000Source |
| Costs and ExpensesUSD | — | — | — | — | 14,275,000Source | 12,547,000Source | 13,370,000Source | 13,315,000Source | 54,346,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 5,605,000Source | 5,355,000Source | 5,757,000Source | 5,617,000Source | 5,432,000Source | 6,162,000Source | 23,867,000Source | 20,156,000Source | 19,254,000Source | 23,685,000Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | — | 377,000Source |
| Interest ExpenseUSD | — | — | 2,000Source | 1,000Source | — | 6,000Source | — | 9,000Source | — | 26,000Source | 416,000Source | — |
| Interest Income, OtherUSD | — | — | 101,000Source | 81,000Source | — | 110,000Source | — | 66,000Source | — | 322,000Source | 424,000Source | — |
| Investment Income, InterestUSD | — | — | — | — | 77,000Source | 110,000Source | 70,000Source | 66,000Source | 386,000Source | — | — | — |
| Management Fee ExpenseUSD | — | — | 3,150,000Source | 2,500,000Source | — | 3,150,000Source | — | 3,150,000Source | — | 11,300,000Source | 9,000,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -10,397,000Source | -12,371,000Source | -14,715,000Source | -7,888,000Source | -23,628,000Source | -36,018,000Source | -70,569,000Source | -53,025,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | — | — | 1,114,000Source | 6,945,000Source | -1,795,000Source | -14,421,000Source | -8,370,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 12,970,000Source | 12,866,000Source | — | 12,547,000Source | — | 13,315,000Source | — | 50,398,000Source | 50,910,000Source | 56,548,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | 2,600,000Source | — | — |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | 3,028,000Source | 3,449,000Source | 9,719,000Source | 9,110,000Source | — | 7,496,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 1,272,000Source | 1,666,000Source | 1,192,000Source | 1,255,000Source | 1,206,000Source | 1,428,000Source | 5,678,000Source | 5,992,000Source | 7,252,000Source | 11,466,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | 1,474,000Source | 1,163,000Source | 1,256,000Source | 828,000Source | 4,706,000Source | — | — | — |
| Selling and Marketing ExpenseUSD | — | — | 4,291,000Source | 4,056,000Source | 5,776,000Source | 4,007,000Source | 5,002,000Source | 4,069,000Source | 17,710,000Source | 16,463,000Source | 16,404,000Source | 16,134,000Source |
| Preferred Stock Dividends, Income Statement Impact | — | — | — | — | — | —Source | — | —Source | — | — | — | — |
Offerings
Registration 333-291981
Filing attachments
ex99-1.htm · 8-K · 2026-09-22
Exhibit 99.1 Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways Medicare Advisory Panel recommends maintaining EsoGuard’s original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response from the CDC/N…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW YORK, August 13, 2026 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical …
Read attachment ↗ex99-1.htm · 8-K · 2026-05-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results Processed 3,177 EsoGuard® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones Conference call and webcast to be held today, May 14, at 8:30 AM EDT NEW YORK, May 14, 2026 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Comp…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-24
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock NEW YORK, April 24, 2026 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per …
Read attachment ↗ex99-1.htm · 8-K · 2026-04-23
EX-99.1 4 ex99-1.htm EX-99.1 Exhibit 99.1 Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock NEW YORK, April 23, 2026 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15M investm…
Read attachment ↗ex107.htm · S-8 · 2026-04-03
Calculation of Filing Fee Tables S-8 Lucid Diagnostics Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registr…
Read attachment ↗